Excipients & Technology

MEGGLE's outstanding product quality and intelligent approach to innovation has secured it a place as a global leader in the manufacture of lactose-based excipients. In this segment, we focus on the production of excipients for direct tabletting and dry powder inhalation. We have now spent over 50 years in developing a broad-based product portfolio that is unique in its market, a fact eloquently confirmed by numerous first-to-market launches. These include:

• Tablettose: first agglomerated lactose for direct tabletting
• Cellactose 80: first co-processed excipient using a cellulose-lactose base with outstanding compression and flow properties
• RetaLac: first co-processed excipient using a hypromellose-lactose base for extended release formulations used in direct tabletting

In our view, the provision of specialist support to our customers in the fields of drug formulation, information services and production process optimisation is both an obligation and an opportunity. This was the thinking behind the opening of our FormulaB Centre of Excellence in Odessa, Ukraine, in 2005. At FormulaB, we not only work on pharmaceutical compounds, but also manufacture clinical trial materials.

Since we also wish to be a competent point of contact for higher education, we naturally pursue close working relationships with researchers at universities and other HE institutions. We also support and supervise a large body of graduate and doctoral thesis work.

"We believe excipient optimisation will continue to show major potential in the future: this is both the justification and motivation for our day-to-day work."